Not sure how much to read into that. Acadia stated their intent to setup in shop Switzerland to support pimavanserin back in their Sept 2015 quarterly.
During the first half of 2015, we licensed worldwide intellectual property rights related to pimavanserin in certain indications to ACADIAPharmaceuticals GmbH, our wholly-owned Swiss subsidiary. Our goals for the establishment of ACADIA Pharmaceuticals GmbH, and the licensing ofworldwide intellectual property rights for pimavanserin, include building a platform for long-term operational and financial efficiencies, including tax-relatedefficiencies.
TROFINETIDE TRIALS UPDATE, page-218
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |